Welcome to our dedicated page for Evolent Health SEC filings (Ticker: EVH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evolent Health, Inc. (NYSE: EVH) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports on Form 8-K, annual and quarterly reports, and other documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Evolent’s specialty care business, capital structure, governance and material events affecting the company.
Through its 8-K filings, Evolent reports results of operations and financial condition, such as quarterly earnings releases that include revenue and adjusted EBITDA, explanations of non-GAAP financial measures and management’s discussion of demand for complex specialty care solutions. Other 8-Ks describe capital markets and financing activities, including the issuance of 4.50% convertible senior notes due 2031, the related indenture terms, and the use of proceeds to repurchase 1.50% convertible senior notes due 2025 and shares of Class A common stock. Amendments to credit agreements and commitment letters for incremental facilities are also disclosed, outlining available debt capital and key conditions.
Evolent’s filings further cover strategic transactions, such as the stock purchase agreement to sell its value-based primary care business, Evolent Care Partners, to Privia Management Company, LLC, and subsequent filings noting consummation of that transaction. Governance and leadership changes are documented under Item 5.02 of Form 8-K, detailing appointments and transitions in executive roles, including the Chief Financial Officer, as well as board retirements and new independent director appointments and related compensation and indemnification arrangements.
Regulatory and legal matters appear in filings as well. For example, Evolent has disclosed receiving a Civil Investigative Demand from the Department of Justice in connection with a False Claims Act investigation related to a former customer and Medicare Advantage diagnosis codes, and has stated that it is cooperating with the government.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of earnings releases, financing agreements, strategic transactions, leadership changes and legal disclosures. Real-time updates from EDGAR ensure that new 8-Ks, 10-Qs, 10-Ks and other forms are available promptly, while structured access to information on insider and executive arrangements can support deeper analysis of Evolent’s corporate governance and compensation practices.
FMR LLC and Abigail P. Johnson filed an amended Schedule 13G reporting their beneficial ownership of Evolent Health’s Class A common stock as of 12/31/2025. They report beneficial ownership of 750,886.96 shares, representing 0.7% of the outstanding Class A common stock.
FMR LLC has sole voting power over 741,735.20 shares and sole dispositive power over 750,886.96 shares. Abigail P. Johnson reports sole dispositive power over 750,886.96 shares with no voting power. The securities are certified as held in the ordinary course of business and not for the purpose of changing or influencing control of Evolent Health.
The Vanguard Group filed an amended Schedule 13G showing beneficial ownership of 8,914,065 shares of Evolent Health Inc common stock, representing 7.98% of the class as of 12/31/2025. Vanguard reports shared voting power over 933,846 shares and shared dispositive power over all 8,914,065 shares, with no sole voting or dispositive power.
The filing explains that Vanguard’s clients, including registered investment companies and other managed accounts, have the economic rights to dividends and sale proceeds, with no single client holding more than 5% of the class. Vanguard notes an internal realignment effective January 12, 2026, after which certain subsidiaries are expected to report holdings separately. Vanguard certifies the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Evolent Health.
Evolent Health, Inc. reported that director Ms. Smith received an equity award of 23,137 restricted stock units of Class A common stock on 01/02/2026. The units were granted at a price of $0 under the Amended and Restated Evolent Health, Inc. 2015 Omnibus Incentive Compensation Plan and are shown as directly owned after the transaction.
The restricted stock units vest on the earlier of January 2, 2027 or the date of the company’s 2026 annual meeting, as long as she continues in service through the vesting date.
Evolent Health, Inc. reported that its Chief Financial Officer received a special one-time restricted stock unit (RSU) grant. On 01/02/2026, the officer acquired 587,500 RSUs for Class A Common Stock at a price of $0 per unit, recorded as a direct holding. The grant was made as an employment inducement award under Rule 303A.08 of the New York Stock Exchange Listing Manual.
The RSUs vest over three years, with 34% scheduled to vest on January 2, 2027 and 33% on each of January 2, 2028 and January 2, 2029, subject to the executive’s continued employment through each vesting date. Upon vesting, each unit converts into one share of Class A Common Stock, aligning the CFO’s compensation more closely with the company’s equity performance.
Evolent Health, Inc. filed an initial insider ownership report for its Chief Financial Officer. The filing shows that, as of the event date of January 2, 2026, the CFO reported beneficial ownership of 0 shares of Class A common stock, held directly. The report also indicates no derivative securities, such as options or warrants, reported as beneficially owned. The form is filed as a single-reporting-person filing and references a Power of Attorney dated December 12, 2025 authorizing execution of the document.
Evolent Health, Inc. filed a Form S-8 to register 587,500 shares of its Class A common stock, $0.01 par value per share. These shares are issuable upon the vesting of restricted stock units granted to Mario Ramos as an inducement for him to accept employment as the company’s Chief Financial Officer, in accordance with Section 303A.08 of the New York Stock Exchange Listed Company Manual.
The awards were approved by the Compensation Committee of the Board of Directors and were granted outside the Evolent Health, Inc. Amended and Restated 2015 Omnibus Incentive Compensation Plan. The filing also describes the company’s standard indemnification and liability protections for directors and officers and lists the exhibits supporting this registration, including the form of the award agreement and legal opinions.
Evolent Health, Inc. reported an initial insider ownership filing for one of its directors. The filing states that as of the event date of December 2, 2025, the reporting person, serving in the role of director, does not beneficially own any shares of Evolent Health common stock or other non-derivative securities. The filing also shows no derivative securities, such as options or warrants, reported as beneficially owned. The document is signed by an attorney-in-fact under a power of attorney dated December 4, 2025, indicating the director’s ownership status is formally recorded as zero at this time.
Evolent Health, Inc. reported that its wholly owned subsidiary, Evolent Health LLC, has completed the transactions under a previously announced Stock Purchase Agreement with Privia Management Company, LLC. The agreement was originally dated September 23, 2025, and the deal was consummated on December 5, 2025. This filing simply confirms the closing of that stock purchase arrangement, indicating that the parties have carried out the terms that were agreed earlier in the year.
Evolent Health, Inc. announced that board member Cheryl Scott retired effective December 1, 2025. In connection with her retirement, the board accelerated the vesting of 21,979 restricted stock units that were previously scheduled to vest around the 2026 annual shareholder meeting.
The board appointed Jill Smith, 67, as a new independent director with a term running until the Company’s 2026 annual meeting. She brings more than 25 years of leadership experience, including chief executive roles at several technology and services companies and multiple public-company directorships.
Evolent also reaffirmed its fourth quarter 2025 outlook, guiding to revenue of approximately $462.0 million to $472.0 million and Adjusted EBITDA of about $30.0 million to $40.0 million, consistent with guidance previously issued in a November 6, 2025 press release.
Evolent Health, Inc. (EVH) reported an insider stock purchase by a director. On 11/18/2025, the director bought 10,000 shares of Class A common stock in an open-market transaction coded "P" at a price of $3.8199 per share. Following this trade, the director beneficially owns 58,821 shares, which include restricted stock units granted under prior awards. The filing is made by a single reporting person in the capacity of director and notes the potential use of a Rule 10b5-1 trading plan checkbox, although no selection detail is provided in this excerpt.